Morgan Stanley Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $120
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)
Blueprint Medicines Analyst Ratings
Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133
TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Raises Target Price to $105
Blueprint Medicines (BPMC) Receives a Hold From Barclays
Blueprint Medicines Price Target Raised to $138.00/Share From $130.00 by Guggenheim
Blueprint Medicines Analyst Ratings
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $120 to $135
Blueprint Medicines Analyst Ratings
Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $130
Buy Rating Affirmed: Blueprint Medicines Surpasses Q2 Revenue Estimates With Ayvakit's Success
Blueprint Medicines Analyst Ratings
Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)
Blueprint Medicines Analyst Ratings